Quinoline

Quinoline

SCHEMBL1257445

CCOCC.c1ccc2ncccc2c1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.68
PDE10A Q9Y233 1/20 0.45
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44
RAB9A P51151 1/20 0.44
CYP3A4 P08684 2/20 0.44
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
TLR8 Q9NR97 1/20 0.42
HTT P42858 3/20 0.41
CASP1 P29466 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 2/20 0.41
MEN1 O00255 1/20 0.41
CASP7 P55210 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2C19 P33261 1/20 0.41
NR4A2 P43354 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL28244243 0.94 ALDH1A1 (0.61) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL2535469 0.87 ALDH1A1 (0.81) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL27960167 0.85 ALDH1A1 (0.77) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL4599170 0.85 ALDH1A1 (0.77) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL28292257 0.83 ALDH1A1 (0.74) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL6399465 0.83 ALDH1A1 (0.74) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL27849601 0.83 ALDH1A1 (0.74) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL4265438 0.83 ALDH1A1 (0.74) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL27467057 0.83 ALDH1A1 (0.74) ALDH1A1PDE10ANPC1POLBRAB9A
Quinoline SCHEMBL28250556 0.83 ALDH1A1 (0.74) ALDH1A1PDE10ANPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109776410-B Heptafluoroisopropyl quinoline ether-containing compound, preparation method and application thereof 浙江省化工研究院有限公司 2021-02-05 CN claimed
CN-109776410-A A kind of ether compound of quinoline containing hepta-fluoroiso-propyl, preparation method and application 浙江省化工研究院有限公司 2019-05-21 CN claimed
CN-102382484-A Polynuclear arene photosensitive material and dye-sensitized solar cell prepared by same UNIV CHINA PETROLEUM 2012-03-21 CN claimed
JP-2076855-A None JP disclosed
CN-120623147-B Pyrazolyl quinoline ether compound and application thereof in preparation of neuroprotective drugs 广东省科学院动物研究所 2025-12-16 CN disclosed
CN-120623147-A Pyrazolyl quinoline ether compound and application thereof in preparation of neuroprotective drugs 广东省科学院动物研究所 2025-09-12 CN disclosed
US-12011423-B2 S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders FORAVISET LTD. (IL) 2024-06-18 US disclosed
WO-2023213740-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS PHILIP MORRIS PRODUCTS S.A. (CH) 2023-11-09 WO disclosed
CN-113549053-B Pyrazoloquine (azolyl) ether compound and application thereof 沈阳中化农药化工研发有限公司 2022-09-13 CN disclosed
CN-109776410-B Heptafluoroisopropyl quinoline ether-containing compound, preparation method and application thereof 浙江省化工研究院有限公司 2021-02-05 CN disclosed
CN-111978156-A Method for preparing cannabidiol 云南汉盟制药有限公司 2020-11-24 CN disclosed
WO-1993008171-A1 PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed
WO-1993008170-A1 SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed
EP-0539086-A2 Condensed pyrimidine derivatives and their use as angiotensine II antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-28 EP disclosed
US-5187168-A Hypotensive agents AMERICAN HOME PRODUCTS CORPORATION (US) 1993-02-16 US disclosed
US-5149699-A Substituted pyridopyrimidines useful as antgiotensin II antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1992-09-22 US disclosed
US-5102881-A Leukotriene biosynthesis inhibitor MERCK FROSST CANADA, INC. (CA) 1992-04-07 US disclosed
CN-1051359-A Improved imidazo [4, the 5-b] quinolinyloxyalkanoic acid amides of water-soluble degree BRISTOL MYERS SQUIBB CO (US) 1991-05-15 CN disclosed
JP-H0276855-A QUINOLINE ETHER ALKANOIC ACID MERCK FROSST CANADA INC 1990-03-16 JP disclosed
EP-0349062-A1 Quinoline ether alkanoic acid MERCK FROSST CANADA INC. (CA) 1990-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12011423-B2 S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders KCNN3, ITPR3, KCNN2 ALDH1A1 2043/4885PDE10A 320/4885NPC1 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.